Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers.

Article Details

Citation
Copy to clipboard

Barrett RJ, Lamson MJ, Johnson J, Smith WB

Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers.

J Nucl Cardiol. 2005 Mar-Apr;12(2):166-71.

PubMed ID
15812370 [ View in PubMed
]
Abstract

BACKGROUND: Binodenoson, a highly selective agonist of the adenosine A 2A receptor, is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging. This study was designed to assess the single-dose pharmacokinetics, safety, and tolerability of intravenous binodenoson. METHODS AND RESULTS: This was a single-center, open-label, nonrandomized, dose-escalation study in 24 healthy volunteers. Each subject received 3 successive intravenous doses of binodenoson (0.1, 0.2, 0.4, 0.6, 1, 2, 3, 4, 5, and 6 microg/kg), each infused over a period of 10 minutes and separated by washout periods of at least 120 minutes. Generally, binodenoson was well tolerated. There were no serious adverse events. However, there was a dose-related increase in adverse events (e.g., headache, nausea, vasodilation, chest pain), consistent with the pharmacology of the drug. Binodenoson exhibited linear pharmacokinetics as indicated by a dose-proportional increase in peak concentration (C max ) and area under the concentration-time curve (AUC). Systemic clearance was independent of dose but was correlated with body weight. The mean terminal half-life of binodenoson across all doses was 10 +/- 4 minutes. CONCLUSIONS: Overall, binodenoson was well tolerated and exhibited linear pharmacokinetics when administered intravenously over a 60-fold dose range from 0.1 to 6 microg/kg.

DrugBank Data that Cites this Article

Drugs